Lung Cancer Research StudiesEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers

PP01.12: Cost-Effectiveness and Budget Impact of Durvalumab Following Concurrent Platinum-Based Chemo-Radiotherapy Versus Surveillance Following Chemo-Radiotherapy in Patients With Limited-Stage Small-Cell Lung Cancer in the United States

William Wang, Iqra Syed, V. Genestier, M. Ract, Daniel Simmons

2026.5.1Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2026.103755

Abstract

Abstract is not available.

Citation format

WANG, William, et al. PP01.12: Cost-effectiveness and budget impact of durvalumab following concurrent platinum-based chemo-radiotherapy versus surveillance following chemo-radiotherapy in patients with limited-stage small-cell lung cancer in the United States. Journal of Thoracic Oncology, 2026, 21(5): 103755.